Stem cell derived factors for treating pathologic conditions

Abstract

A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.

1 - 15 . (canceled) 
     
     
         16 . A pharmaceutical composition comprising a purified paracrine factor of a mesenchymal stem cell (MSC), wherein said factor comprises SEQ ID NO:17 or a fragment thereof and one or more pharmaceutically acceptable excipients. 
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein the pharmaceutically acceptable excipient is one or more of isotonic saline, glucose, cyclodextrin, or polyvinylpyrrolidone (PVP). 
     
     
         18 . The pharmaceutical composition of  claim 16 , wherein the composition is formulated for oral, nasal, topical, parenteral, subcutaneous, intraperitoneal, intramuscular, or intravenous administration. 
     
     
         19 . The pharmaceutical composition of  claim 16 , wherein the composition is formulated for direct intracoronary injection (a) through the chest wall; (b) into a coronary artery; or (c) using percutaneous catheter-based methods. 
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the composition is formulated for injection into myocardium, pericardium, or endocardium. 
     
     
         21 . The pharmaceutical composition of  claim 16 , wherein the composition is formulated into a capsule or a tablet for oral administration, ointment, suppository, paste, spray, dermal patch, cream, gel, resorbable sponge, or foam. 
     
     
         22 . The pharmaceutical composition of  claim 16 , wherein the composition further comprises one or more of (a) an anti-apoptotic agent; or (b) a therapeutic agent for treating, preventing, or alleviating a symptom of a cardiac disorder. 
     
     
         23 . The pharmaceutical composition of  claim 16 , wherein the composition further comprises one or more of VEGF, thyrosin beta 4, Sfrp-1, Sfrp-2, Sfrp-3, adipsin, adrenomedullin, chemokine (C—C motif) ligand 2, cysteine rich protein 61, lysyl oxidase-like 2, or a serine proteinase inhibitor. 
     
     
         24 . The pharmaceutical composition of  claim 16 , wherein the composition comprises at least 60%, 75%, 90%, or 99% by weight of SEQ ID NO:17 or a fragment thereof. 
     
     
         25 . The pharmaceutical composition of  claim 16 , wherein said factor comprises amino acids 45-430 of SEQ ID NO:17. 
     
     
         26 . The pharmaceutical composition of  claim 21 , wherein said composition is a slow-release composition. 
     
     
         27 . The pharmaceutical composition of  claim 16 , wherein said composition is formulated for administration to brain or spinal cord. 
     
     
         28 . The pharmaceutical composition of  claim 16 , wherein said pharmaceutically acceptable excipients comprise one or more of an isotonic saline solution, a glucose solution, polyvinylpyrrolidone (PVP), cyclodextrins, or another standard pharmaceutically acceptable excipient. 
     
     
         29 . The pharmaceutical composition of  claim 21 , wherein the composition is formulated into a capsule or a tablet for oral administration and further comprises one or more of a cytoprotective compound, gelatin, cellulose, starch, sugar bentonite, a lubricant, lactose, mannitol, a filler, or a tableting agent. 
     
     
         30 . The pharmaceutical composition of  claim 16 , comprising about 0.1 mg/kg to about 150 mg/kg of the polypeptide encoded by SEQ ID NO:17 or a fragment thereof. 
     
     
         31 . The pharmaceutical composition of  claim 20 , comprising 1-1000 μg of the polypeptide encoded by SEQ ID NO:17 or a fragment thereof. 
     
     
         32 . A stent or catheter comprising the pharmaceutical formulation of  claim 16 .